Diserinal

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diserinal

What is Diserinal? Foundational Identity

This section provides a factual overview of Diserinal, establishing its composition, classification, and general purpose without addressing specific clinical treatments, dosages, or safety information.

Property Description
Active ingredient Alfacalcidol (1-alpha-hydroxycholecalciferol)
Form Oral formulations (typically soft capsules or oral drops)
Pharmacological class Vitamin D and Analogues (ATC A11CC03)
Common purpose To support calcium and phosphate homeostasis
Origin Synthetic analogue (non-endogenous prodrug)

Classification and Origin

Diserinal is defined by its active ingredient, Alfacalcidol, which places it in the pharmacological class of Vitamin D analogues. It is a manufactured, synthetic derivative that functions as a prodrug—an inactive compound that transforms into an active agent after administration. The medication is supplied for oral administration, typically as soft capsules or oral drops.

Unlike naturally occurring Vitamin D, which requires two activation steps in the body, Alfacalcidol is already chemically modified. This unique structure means the compound does not require the specific 1alpha-hydroxylation step that occurs in the kidney. This characteristic ensures that the body can reliably produce the final active hormone, calcitriol, even when kidney function is compromised.


Unique Role in Mineral Balance

The fundamental purpose of Diserinal is to support the body's essential process of maintaining calcium and phosphate homeostasis. Alfacalcidol is recognized in relevant populations for its role as a Vitamin D analogue in managing disorders of bone and calcium metabolism.

Its underlying action relies on rapid conversion in the liver to calcitriol, the compound responsible for stimulating intestinal calcium absorption. By bypassing the final activation step normally performed by the kidney, Alfacalcidol is particularly suited for maintaining bone metabolism in individuals with impaired renal function, whose ability to activate Vitamin D naturally is reduced.

What side effects are possible with Diserinal?

Possible Side Effects and Safety Information: Diserinal

Diserinal (desloratadine) is generally well-tolerated. However, like all medications, it can cause side effects, although not everyone experiences them. Most side effects are mild and transient, often resolving as the body adjusts to the medication.


Common Side Effects

In clinical trials, the most frequently reported adverse reactions, occurring slightly more often than with placebo, included:

  • Fatigue
  • Dry mouth
  • Headache

Less Common and Serious Side Effects

Less frequently, other adverse events have been reported during post-marketing surveillance or clinical trials. While rare, patients should be aware of these potential effects and contact a healthcare provider if they experience them. These include dizziness, somnolence, insomnia, and gastrointestinal disturbances such as nausea, vomiting, or abdominal pain. Very rare, but serious, effects have included hallucinations, seizures, psychomotor hyperactivity, tachycardia, palpitations, liver enzyme elevations, and hepatitis/jaundice. Discontinuation may be considered if a seizure occurs during treatment.


Important Safety Information

Hepatic and Renal Impairment: Diserinal should be used with caution in patients with severe hepatic (liver) impairment, as hepatitis and jaundice are possible adverse reactions. Caution is also advised in cases of severe renal (kidney) insufficiency.

Seizures: Patients with a medical or family history of seizures, particularly young children, should use this medication with caution.

Pregnancy and Breast-feeding: It is generally recommended to avoid the use of desloratadine during pregnancy as a precautionary measure. Desloratadine is excreted in breast milk. A healthcare provider must weigh the benefits of breast-feeding against the benefit of therapy for the mother.

Operating Machinery: While Diserinal has a negligible effect on the ability to drive or use machines for most individuals, individual responses vary. Patients should not engage in activities requiring mental alertness until they know how the medicine affects them.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile of Diserinal (Alfacalcidol) primarily by the risk of hypercalcemia (high blood calcium levels) and subsequent severe organ damage.

Documented Overdose Manifestations and Risks

Feature Official Regulatory Statement
Documented Presentations Overdose frequently presents with signs of hypercalcemia, including anorexia, nausea, vomiting, weakness, headache, metallic taste, and excessive thirst or urination (polyuria).
Serious Outcomes Documented risks include the potential for renal failure, nephrocalcinosis, and serious effects on the cardiovascular system, such as hypertension and cardiac arrhythmias. Prolonged hypercalcemia can lead to irreversible soft-tissue and vascular calcification.
Population-Specific Note Close monitoring is cited as especially critical for patients receiving digitalis glycosides, due to a heightened potential for cardiac arrhythmias if hypercalcemia occurs.

Emergency Actions and Management

Feature Official Regulatory Statement
Immediate Action Required Individuals must seek immediate medical attention upon known or suspected overdose. Regulators mandate that patients contact emergency services or a poison control centre immediately, even in the absence of current symptoms, as hypercalcemia may rapidly escalate.
Officially Described Management Management involves the immediate discontinuation of Diserinal and calcium supplements. Hospital monitoring is required, including serial serum calcium levels and ECG assessments. Supportive measures include forced diuresis. No specific antidote is known.

The regulatory profile strictly links overexposure to a severe metabolic risk, necessitating immediate professional intervention. The documented potential for acute, severe, or long-term organ damage from hypercalcemia defines the mandatory requirement to seek urgent medical attention, regardless of initial symptom severity.

Therapeutic Uses of Diserinal

What Diserinal Treats: Main Uses and Benefits

Diserinal is relevant in the therapeutic domain of managing disorders related to calcium, phosphate, and bone metabolism. Its primary benefit is in providing a source of activated Vitamin D to help with systemic imbalance and supports skeletal integrity in specific patient populations.


The medication is commonly used to help with conditions marked by systemic physiological stress, including renal osteodystrophy (bone disease in chronic kidney failure), secondary hyperparathyroidism, hypocalcaemia (low blood calcium), rickets (in children), and osteomalacia (in adults). In these settings, Diserinal provides continuous support to help maintain essential mineral homeostasis. It is applied when additional symptomatic support is needed, primarily addressing bone pain, skeletal fragility, and the muscle cramps associated with low calcium.

“This therapeutic agent plays a role in managing bone mineralization and assists with maintaining skeletal stability in situations where the ability to activate Vitamin D naturally is impaired.”


Quick Fact: Relief for Bone Pain and Cramping
Diserinal is relevant for supportive symptom management of calcium and phosphate levels, which contributes to easing the overall burden of bone pain and may assist with neuromuscular symptoms (like cramps) that arise from chronic mineral deficiencies.

Regulatory References

  1. World Health Organization Essential Medicines List review

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Diserinal — official regulatory information


Eligibility Scope

Classification Population Group Regulatory Statement
Populations for whom use is allowed Adults with chronic renal failure, hypoparathyroidism, rickets, or osteomalacia. Indicated for management of related mineral disorders.
Populations for whom use is contraindicated Patients with Hypercalcaemia, Metastatic Calcification, Vitamin D Overdose, or Hypersensitivity to alfacalcidol or formulation excipients. Use is absolutely forbidden.
Populations for whom use is not recommended Pregnant and Breastfeeding Women. Use must be avoided unless clearly necessary.

Age-related eligibility rules

  • Pediatric Patients: Safety and efficacy are not established for some formulations or in all regions, though use is permitted in others.
  • Geriatric Patients: Data supporting an indication may be unavailable in some jurisdictions.

Condition-specific eligibility rules

  • Requires Caution: Patients with granulomatous diseases (e.g., sarcoidosis) or a history of renal calculi (kidney stones).
  • Renal Impairment: Not a contraindication, but requires regular monitoring of serum calcium, phosphate, and creatinine.

Eligibility classifications (high-level)

Classification Term Definition
Eligibility severity classification Contraindicated (Prohibition); Not Recommended (Avoided); Caution (Permitted with close monitoring).

Connection to the overall eligibility profile

The official profile is defined by absolute contraindications based on elevated mineral levels (hypercalcaemia) or hypersensitivity. Use is permitted for specific renal and metabolic bone disorders but is heavily restricted for special physiological states, with use categorized as not established or not recommended for critical groups like children and pregnant women.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Restrictions and Prohibitions

The regulatory label strictly defines combinations that are contraindicated or must be avoided. Co-administration with other Vitamin D analogues or preparations is prohibited due to the significant, additive risk of hypercalcaemia. Use with Digitalis glycosides (e.g., Digoxin) is a formal contraindication if hypercalcaemia is present, as this condition increases the potential for cardiac arrhythmias.

Exposure-Altering Interactions

Pharmacodynamic interactions occur with substances that independently raise calcium levels, such as thiazide diuretics and calcium-containing supplements, which enhance the overall risk of hypercalcaemia. Drugs that induce hepatic enzymes, like certain anticonvulsants (e.g., Phenytoin), can increase the metabolism of Alfacalcidol, potentially reducing its exposure. Furthermore, Diserinal may enhance the systemic absorption of both aluminium and magnesium compounds, elevating the risk of associated toxicities.

Timing and Population Cautions

To prevent impaired absorption by compounds like bile acid sequestrants (e.g., Cholestyramine), the official label requires Diserinal to be administered separated by a mandatory timing rule: at least one hour before, or four to six hours after the sequestrant. Specific interaction cautions exist for populations with compromised elimination; the risk of hypermagnesaemia from antacids is heightened for patients on chronic renal dialysis.

Mechanism of Action

How Diserinal Works

Diserinal's active mechanism is defined by its targeted action as a prodrug for calcitriol, the regulator of mineral homeostasis. The process involves a specific sequence of molecular events that result in physiological adjustments.


Bypass of Renal Activation and VDR Agonism

The core mechanism involves bypassing the kidney's 1alpha-hydroxylation step, which is unique to Alfacalcidol. The drug relies only on hepatic 25-hydroxylation to produce the active hormone, calcitriol . Calcitriol then acts as a high-affinity agonist for the Vitamin D Receptor (VDR), an intracellular nuclear receptor. This mechanism of activation and VDR-binding initiates the genomic signaling that controls mineral regulation throughout the body.


Modulation of Calcium and Phosphate Homeostasis

The VDR activation triggers transcriptional modulation, leading to the enhanced expression of critical transport proteins, such as Calbindin, within the intestinal cells and renal tubules. This molecular action results in a coordinated increase in the absorption of calcium and phosphate from the diet and their reabsorption from the kidney. These physiological changes work to raise the circulating concentrations of these minerals, which alters circulating concentrations.


Negative Feedback on the Parathyroid Hormone (PTH) Axis

The resulting rise in serum calcium and the direct VDR agonism in the parathyroid glands generate a negative feedback loop. This mechanism suppresses the synthesis and release of Parathyroid Hormone (PTH), a key regulatory hormone for mineral flux. The suppression of PTH, combined with normalized mineral concentrations, modulates the metabolic state, influencing bone dynamics and systemic mineral regulation.

Dosage and Administration Information

How to use Diserinal

Diserinal (Alfacalcidol) is administered primarily via the oral route as capsules or liquid drops, though an intravenous form is also officially approved for specific clinical settings. The entire treatment protocol is based on a controlled, titratable regimen that mandates adherence to official schedules.

The standard initial dose for most adults is 1.0 μg once daily. Patients beginning treatment for chronic renal failure often initiate therapy with a lower 0.25 μg dose daily. Dosing is highly individualized, and maintenance adjustments are typically performed in 0.25 μg increments only after designated monitoring intervals of two to four weeks have passed.

Official use instructions specify that the medicine may be taken with or without food. However, a necessary procedural constraint requires separating the intake from bile acid sequestrants by at least one hour before or four to six hours after to ensure proper absorption. Furthermore, the treatment protocol mandates that patients receive an adequate daily calcium intake. If a dose is missed, patients should take it when remembered, but must not take a double dose. The dosage is also modified for age groups, with distinct initial doses established for older adults and pediatric patients based on body weight.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diserinal

ὐe Evidence for Use in Chronic Kidney Disease-Related Bone Disorders

Research has extensively examined the use of Diserinal in adults with Chronic Kidney Disease (CKD), including those on dialysis, focusing on conditions characterized by systemic or functional imbalance in mineral metabolism. Studies often use large-scale Randomized Controlled Trials (RCTs) and meta-analyses to explore outcomes related to systemic imbalance, specifically the high levels of Parathyroid Hormone (PTH). Studies monitored shifts in PTH, serum calcium, and serum phosphate levels. The research explored the potential for changes in PTH levels, and some research explores the association between these biochemical changes and bone histological markers.

Long-term effects are not fully established regarding major clinical outcomes, such as fatal or non-fatal cardiovascular events and all-cause mortality. Some large RCTs examined these outcomes and reported mixed findings or non-significant associations.

ᾛ4 Evidence for Bone Mineralization Disorders (Rickets and Osteomalacia)

Diserinal was studied for its use in individuals with disorders like rickets (in children) and osteomalacia (in adults), which are conditions marked by functional limitations. The evidence base includes older clinical reports and trials that explored mineral balance in individuals where the kidney's ability to activate Vitamin D is impaired. These studies research examined whether the treatment was associated with changes in serum calcium levels. Furthermore, some research used invasive methods, such as bone biopsies, to obtain histological measurements that showed patterns related to measured levels of unmineralized bone (osteoid).

ᾜd‍️ Evidence for Osteoporosis and Skeletal Integrity

Diserinal was evaluated in trials involving postmenopausal women and elderly men and women with osteoporosis. These studies monitored changes in Bone Mineral Density (BMD) and measured the incidence of new vertebral and non-vertebral fractures. Findings from different studies showed patterns related to changes in BMD levels. Some research explored whether the use of Diserinal alongside other treatments was associated with specific measurement patterns compared to groups that received a single intervention.

Ὂ1 What Remains Uncertain or Under Research

Research highlights what is known — and what is still uncertain — about Diserinal. A key area of uncertainty is the precise long-term impact on cardiovascular health and overall survival in individuals with CKD, where trial results have findings that were mixed. Research continues to examine the relationship between PTH suppression and measured hypercalcemia and hyperphosphatemia. For indications like osteoporosis, the certainty remains low regarding whether the treatment, when used alone, provides a consistent and measurable reduction in non-vertebral fracture incidence.

Key Studies & References A.2 Alfacalcidol and calcitriol – disorders of bone and calcium metabolism – EML and EMLc (WHO 2023 Expert Review)

Frequently Asked Questions (FAQ)

Common questions about Diserinal (FAQ)


Q: How quickly can a person generally expect Diserinal to start working?

Official pharmacological information indicates that the therapeutic effect, which is the desired change in mineral levels, is typically achieved in approximately 3 to 5 days after initiating treatment with Diserinal (Alfacalcidol). This timing refers to the biochemical effect; individual therapeutic response may vary.


Q: How long does the effect of one dose of Diserinal usually last?

The active form of Diserinal (calcitriol) has a biological half-life of roughly 36 hours in the serum. This indicates a relatively prolonged presence in the body, where the impact on mineral levels is sustained.


Q: Does Diserinal have any interactions with common over-the-counter pain relievers?

Regulatory documents list specific interactions with certain drug classes, such as diuretics and anticonvulsants. Official regulatory labels do not commonly list interactions with standard pain relievers such as acetaminophen or non-steroidal anti-inflammatory drugs (NSAIDs).


Q: Is there a generic version of Diserinal available?

Yes, products containing the active ingredient, Alfacalcidol, are manufactured and available under multiple generic names, in addition to the various brand names, across different countries globally.


Q: Does Diserinal interact with alcohol?

While there is no universally listed direct drug-alcohol interaction, some patient guidance recommends limiting or avoiding alcohol consumption. This guidance is provided because alcohol may potentially affect calcium absorption.


Q: Is Diserinal a controlled substance or habit-forming?

No. Diserinal (Alfacalcidol) is classified as a Vitamin D analogue. It is not listed as a controlled substance and is not considered to be habit-forming by major regulatory bodies.


Q: What is the typical length of time a person stays on Diserinal?

The medicine is indicated for the management of chronic conditions related to mineral imbalance, such as renal osteodystrophy. Treatment is often long-term, and continuous monitoring of calcium and phosphate levels is necessary.


Q: Does Diserinal cause weight gain or weight loss?

Weight loss is not listed as a direct side effect of Diserinal. However, loss of appetite and weight loss are reported in association with the symptoms of hypercalcaemia (abnormally high blood calcium levels), which is a known potential symptom associated with hypercalcaemia, a possible side effect of the medicine.


Q: Can Diserinal be crushed, cut, or chewed?

Official instructions indicate that the capsules should typically be swallowed whole with water and not be altered physically. The physical form of the medicine should not be crushed, cut, broken, or opened.


Q: Does Diserinal come with a Medication Guide or Patient Information Sheet?

Yes. Regulatory guidelines require that all prescription medicines, including Diserinal, are dispensed with an official Patient Information Leaflet or a similar Patient Medication Information sheet to inform users of the drug's proper use, risks, and storage.


Q: Does Diserinal have a risk of withdrawal symptoms?

Regulatory literature indicates that the therapeutic effects of potent Vitamin D forms like Diserinal are reversed rapidly upon withdrawal. This means that mineral levels may quickly return to their pre-treatment state, necessitating ongoing monitoring.


Q: Can someone who is allergic to aspirin take Diserinal?

Official drug labels list specific contraindications and known drug interactions for Diserinal. There is no specific interaction or cross-allergy listed on regulatory documents between Alfacalcidol and aspirin (acetylsalicylic acid).


Q: How soon after stopping Diserinal does it leave the body?

The active compound has a biological half-life of approximately 36 hours. If the medication is discontinued, serum calcium levels generally normalize within a few days to a week, and the effects are reversed relatively quickly.


Q: What is the regulatory status of Diserinal in other major countries?

Diserinal (Alfacalcidol) is a widely recognized medicine. It is authorized and used in many countries globally, including those regulated by the EMA, Health Canada, and the MHRA, for managing disorders of mineral metabolism.


Q: Is Diserinal available over-the-counter anywhere?

No. Regulatory authorities globally classify Diserinal (Alfacalcidol) as a prescription-only medicine (POM) due to its potent mechanism and the requirement for strict medical supervision and monitoring.


Q: Does Diserinal interact with caffeine?

Official drug labels do not list a direct interaction with caffeine. However, some patient guidance suggests it is prudent to avoid or reduce high caffeine intake, as large amounts may potentially interfere with calcium absorption.


Q: What is the maximum duration of use reported in major clinical trials for Diserinal?

Major randomized controlled trials have reported on the effects and safety of continuous Alfacalcidol treatment lasting 18 months or longer. These studies provide evidence for its use in chronic conditions, subject to regular monitoring.


Q: Why is Diserinal considered a prescription-only drug?

Diserinal is a potent active hormonal therapy that bypasses the body's natural regulatory process. It is prescription-only because it requires strict medical supervision, precise dose titration, and mandatory, regular monitoring of blood calcium and phosphate levels to prevent serious side effects.


Q: Is the side effect profile of Diserinal dose-dependent?

Yes. According to regulatory safety information, the risk of serious side effects, particularly hypercalcaemia (high blood calcium) and high phosphate levels, is directly linked to the dose of the medicine. Close monitoring is essential to manage this risk.


Q: Is Diserinal the same as other similar medicines I've heard about?

Diserinal (Alfacalcidol) is a synthetic Vitamin D analogue that is a unique prodrug for calcitriol. Its key difference from standard Vitamin D is that it bypasses the final activation step normally performed in the kidney, which makes it particularly relevant for people with impaired kidney function.


Q: Can Diserinal be taken with herbal supplements or vitamins?

Due to the risk of excessive mineral levels, official labeling prohibits taking Diserinal with other Vitamin D analogues and cautions against supplements containing high amounts of calcium or magnesium. It is important to discuss all herbal supplements and vitamins with your healthcare provider.


Q: Is Diserinal safe for older adults or elderly people?

Diserinal is often used in older adults, but regulatory labels note that dosing is individualized and may be modified for this age group. Close monitoring is typically recommended for patients in this group to address the risk of hypercalcaemia, though data supporting the indication may vary by region.


Q: What types of food or drinks should be avoided while taking Diserinal?

Diserinal can be taken with or without food. However, caution is advised regarding foods and supplements that significantly increase calcium or magnesium intake, as this increases the risk of side effects. Intake should also be separated by a specific time interval from bile acid sequestrants (used for lowering cholesterol).


Q: Why might a person need to stop taking Diserinal suddenly?

Regulatory guidelines state that Diserinal should be discontinued immediately if hypercalcaemia (excessive calcium in the blood) occurs, or if a seizure occurs during treatment. These are signs of potentially serious effects described in the safety information.


Q: What should be done if an unexpected symptom occurs while on Diserinal?

While specific serious side effects are listed on the label, official patient guidance states that any unexpected symptoms or side effects should be reported to a healthcare professional.


Q: How does Diserinal compare to older medicines used for the same condition?

Factual comparison focuses on the mechanism of action. Diserinal is a prodrug that requires only hepatic activation (in the liver). This characteristic allows it to bypass the final activation step that older forms of Vitamin D require from the kidneys.


Q: Why do some people experience better results with Diserinal than others?

Patient response can vary because the dosing is highly individualized and must be adjusted based on blood test results. Clinical studies on major long-term outcomes have also reported mixed findings, suggesting that individual patient factors and co-existing chronic conditions play a significant role in overall results.


Q: What should be discussed with a healthcare provider before starting Diserinal?

You should discuss any existing conditions such as seizures, kidney stones, severe hepatic/renal impairment, or granulomatous diseases. Regulatory caution notes the importance of discussing the use of other Vitamin D analogues, Digoxin, or any supplements containing high levels of calcium or magnesium.


Q: Are there any official warnings or boxed warnings for Diserinal?

Official regulatory information includes Important Safety Information and absolute contraindications based on conditions like hypercalcaemia. While the label contains these serious warnings, it may not carry a formal 'Black Box Warning' (the highest-level regulatory warning) in all jurisdictions.


Q: How is the benefit-risk profile of Diserinal generally described by regulatory agencies?

Regulatory agencies authorize Diserinal for its role in managing mineral imbalances in specific populations, noting that the benefit is considered favorable relative to the known risks when required close monitoring is maintained.

How should Diserinal be stored and disposed of?

How to Store and Dispose of Diserinal?

The storage and disposal instructions for Diserinal must adhere strictly to the information provided on its official regulatory labeling, which varies based on the formulation (capsules or oral drops).

Storage Component Official Requirement
Temperature (Capsules) Store at room temperature, typically below 25 C or 30 C.
Temperature (Drops) Must be stored in a refrigerator (e.g., 2 C to 8 C).
Handling Restrictions Do not freeze the product.
Environmental Protection Protect the medicine from both light and moisture.
Child Safety Keep out of the sight and reach of children.
In-Use Stability For oral drops, the product typically has a post-opening shelf-life (e.g., discard any remainder after 4 months of first use).
Disposal Do not dispose of unused or expired medicine in wastewater or household trash. Follow local or national regulations for proper pharmaceutical waste disposal.

Storage conditions are dictated by the drug’s stability profile, which mandates specific temperature ranges and light/moisture protection, often requiring the original packaging to be used. Disposal must follow officially established procedures for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diserinal found in:

A-Z Index: